- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
- TransCode Therapeutics Open Letter to Shareholders
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
- TransCode Therapeutics Reports 2023 Results; Provides Business Update
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
More ▼
Key statistics
On Thursday, Transcode Therapeutics Inc (RNAZ:NAQ) closed at 1.64, 290.48% above the 52 week low of 0.42 set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.51 |
---|---|
High | 1.70 |
Low | 1.48 |
Bid | 1.64 |
Offer | 1.65 |
Previous close | 1.45 |
Average volume | 1.62m |
---|---|
Shares outstanding | 6.62m |
Free float | 6.61m |
P/E (TTM) | -- |
Market cap | 11.75m USD |
EPS (TTM) | -206.36 USD |
Data delayed at least 15 minutes, as of May 30 2024 21:00 BST.
More ▼